The product value added of most enterprises is low

Source: International Business Daily, April 22, 2014, learned from China Chamber of Commerce for the import and export of medical and health care products (hereinafter referred to as the chamber of Commerce for medical insurance) that at present, the internationalization process of Chinese pharmaceutical enterprises is accelerating According to the data, in 2013, China exported 66 kinds of Western medicine preparations to 173 countries and regions, with the export value of Western medicine preparations reaching US $2.711 billion, up 5.82% year on year At present, there are nearly 50 domestic enterprises that have reached the GMP standards of Europe, the United States, Japan and who, and more than 10 enterprises and 30 products that have successfully applied for anda in the United States However, the whole export of preparations is still in a dual structure: a small number of enterprises are in the upper layer of the structure, and most enterprises are producing low value-added products Finally, the situation is: good and better, ordinary enterprises are difficult to transform Small and medium-sized enterprises: enterprises such as Huahai, Haizheng and dongyangguang are at the top of the dual structure, but most of them are basically low value-added products, or their preparations are mainly to meet domestic demand Xu Ming, vice president of the chamber of Commerce for medical insurance, told the international business daily that in the current domestic pharmaceutical market, enterprises are facing more and more difficulties in production and do not have enough funds to invest in research and development "But for the export of preparations, as a chamber of Commerce, on the one hand, we need to help the leading enterprises At the" China and the world pharmaceutical Summit Forum "held the day before this year's exhibition, we will issue the third batch of modern international leading enterprises We need to help them, including certification and registration, develop new international marketing channels, including pricing Recently, we are making some comments on how to enter the European market and how to talk with purchasing agencies like the UK NHS For those who do not have access to the high-end market, we propose "encircling the city by the countryside" For example, in the African market, you can enter the African market first, stand firm, and then gradually move to the markets of developed countries such as Europe and the United States " Xu Ming said When talking about promoting domestic small and medium-sized pharmaceutical enterprises to open the international market, Xu Ming said: "the chamber of Commerce for medical insurance will do a trade promotion activity this year, and the threshold for emerging markets is relatively low now In recent years, African drug procurement has to enter the WHO PQ to reach the WHO GMP, but it is also of three categories There is no problem with ordinary antibiotics, reaching the Chinese GMP, and it is much easier to enter the African market than the European and American market There are also some underdeveloped countries in Asia and some Latin American countries After entering these countries and slowly building their brands, they will go to apply for European and American certification, forming a trend of Encircling Cities in rural areas It is recommended that enterprises not rush to focus on European and American markets " Leading enterprise: when talking about the internationalization of preparations, Xu Ming said that China's preparations export potential is huge "Last year, China exported 2.7 billion preparations and 23.6 billion APIs, which shows the difference Huahai launched more than ten andas in the United States last year, and lamotrigine was launched in the United States at the beginning of last year By December last year, Huahai had put one hundred million yuan into the bag This year, we will launch new products Last year, we not only did anda in the United States, but also did P4 challenges To carry out patent challenges is a revolutionary breakthrough for generic pharmaceutical enterprises, and some people have begun to eat crabs It was originally Indian patents, European and American patents, Israeli patents, but not our Chinese enterprises In addition to anda and P4, the pass rate of phase II clinical treatment in the United States is only 30% and 40% If the drug can pass through phase II, it will not be far to enter the final market Haizheng's treatment of hereditary hyperlipidemia has entered the second phase of clinical practice in the United States At present, there are more than a dozen products declared by Chinese enterprises in the FDA for anda, including generic drugs in Europe This fully shows that the development of Chinese enterprises has exceeded expectations This year, the preparation area has been expanded, from point to area Originally, these preparation enterprises are scattered in different areas of various exhibitions This year, we opened a special preparation area in W3 Museum There is no preparation exhibition in the world We need to innovate in CPHI China exhibition This year, we have a preparation area in W3 Museum "